Abstract：
Gender affirming treatment in transgender women is based on a combination of antiandrogens and estrogens, with the latter maintained over the long term. When prescribing these treatments, we must consider the possibility of developing estrogen-dependent breast cancer. In transgender women, a breast cancer incidence of 4.1 per 100,000 has been estimated, which would increase the risk by 46% in relation to cisgender men but decrease it by 70% in relation to cisgender women. It is known that certain gene mutations such as BRCA1 imply an increased risk of breast cancer, but at present the risk in transgender women with BRCA1 treated with estrogens is not well established. We present the case of a transgender woman with a family history of breast cancer and BRCA1 mutation and the therapeutic decisions made in a multidisciplinary team. Following this case, we review and discuss the published literature.
摘要：
变性女性的性别确认治疗基于抗雄激素和雌激素的组合，后者长期维持。当开出这些治疗方法时，我们必须考虑发展雌激素依赖型乳腺癌的可能性。在变性女性中，据估计，乳腺癌发病率为每100,000人中有4.1人，与顺性男性相比，这将使风险增加46%，但与顺性女性相比，风险降低70%。众所周知，某些基因突变如BRCA1意味着乳腺癌的风险增加，但目前,接受雌激素治疗的BRCA1变性女性的风险尚不明确.我们介绍了一名具有乳腺癌家族史和BRCA1突变的变性女性，以及多学科团队做出的治疗决定。在这个案子之后,我们回顾和讨论已发表的文献。
